Clinical trial company Synexus has appointed new board members to support the company’ international expansion.

Charles Woler will take up the role of chairman of the board. Woler’s previous roles include chief executive of Roche France, chairman of SmithKline Beecham’s pharmaceutical business and chief executive of Cadus Pharmaceuticals. 

Benjamin Harrild, Hywel Evans, Ged Gould and Simon Braham have also joined the company’s board as non-executives.

Christophe Berthoux, chief executive of Synexus, said: “We are delighted with the strength of our new board and the expertise they bring. We are confident the new board will help us deliver the ambitious plans we have to expand not only geographically with new research centres but also in broadening the number of therapy areas we offer to our pharma and CRO clients.”